Log in to search using one of your social media accounts:

Drug Development Technology Drug Development Technology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

X4 Pharmaceuticals begins Phase II trial of X4P-001 to treat ccRCC
US-based biotechnology firm X4 Pharmaceuticals has begun the Phase II portion of its ongoing Phase I/II clinical trial with dosing of X4P-001 in combination with Inlyta (axitinib) in advanced clear cell renal cell carcinoma (ccRCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

Tracon Pharma commences dosing in Phase I/II trial of TRC253 to treat mCRPC
US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has started dosing patients in the Phase I/II clinical trial of TRC253 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: Bioverativ Therapeutics, Horizon Pharma
Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Elite Pharmaceuticals, Recordati, GlycoMimetics
US-based Elite Pharmaceuticals has acquired an approved abbreviated new drug application (ANDA) from Mikah Pharma for Trimipramine Maleate Capsules, a generic version of tricyclic antidepressant Surmontil. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

Studying Biophysical Applications of Calorimetric Methods
Under specific physiological conditions, unfolded proteins fold into thermodynamically favourable native structures to gain function. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

Neurocrine ’s Ingrezza fails to meet primary endpoint in Phase II trial for Tourette syndrome
US-based biotechnology firm Neurocrine Biosciences ’ Ingrezza (valbenazine) has failed to meet the primary endpoint in its Phase II T-Force GREEN clinical trial to treat Tourette syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news

Akebia doses first patient in Phase II trial of vadadustat to treat DD-CKD
US-based biopharmaceutical firm Akebia Therapeutics has started dosing patients in its Phase II FO2RWARD clinical trial of vadadustat for the treatment of patients with dialysis-dependent chronic kidney disease (DD-CKD). (Source: Drug Development Technology)
Source: Drug Development Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news

Northwestern Medicine initiates Phase I trial of stem cells + cold virus for glioma
US-based advanced healthcare solutions provider Northwestern Medicine has initiated the Phase I trial of a new neural stem-cell therapy in combination with a common cold virus to detect and destroy brain cancer in patients with malignant glioma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news

Explaining Biosimilars
Pharmaceutical consulting and generic drug professionals: What is your hedge against the financial risk associated with increasingly crowded traditional drug markets? (Source: Drug Development Technology)
Source: Drug Development Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial of HP Acthar gel to manage exacerbations in relapsing and remitting multiple sclerosis (RRMS) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca ’s Phase III trial shows benralizumab minimises OCS use in asthma patients
AstraZeneca has reported positive results from its Phase III clinical trial of benralizumab in combination with standard-of-care treatment for patients with severe asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news

UNS reports positive results from Phase I trial of UB-311 to treat Alzheimer ’s disease
United Neuroscience (UNS) has reported positive results from the Phase I clinical trial of UB-311 for the treatment of patients suffering from Alzheimer ’s disease (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news

Amgen ’s Repatha shows positive outcome in Phase III trial for cardiovascular disease
US-based biopharmaceutical firm Amgen has reported positive outcome for Repatha (evolocumab) in the Phase III FOURIER trial to treat patients suffering from cardiovascular disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 22, 2017 Category: Pharmaceuticals Source Type: news

ViaCyte to study PEC-Direct in international clinical trial for type 1 diabetes
US-based regenerative medicine firm ViaCyte has obtained approval for its investigational new drug (IND) application from both the US Food and Drug Administration and Health Canada to initiate a clinical trial for investigating PEC-Direct in patients … (Source: Drug Development Technology)
Source: Drug Development Technology - May 22, 2017 Category: Pharmaceuticals Source Type: news

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of ozanimod for the treatment of relapsing multiple sclerosis (RMS) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 22, 2017 Category: Pharmaceuticals Source Type: news

Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis
Myovant Sciences has reported positive results from the Phase II clinical trial of relugolix in Japan to treat pain associated with endometriosis in women. (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Majority of UC Cases Considered Mild to Moderate
Publication Date: Month 2017 Ulcerative colitis (UC) can be a significant cause of morbidity and worsen the quality of life for individuals with the disease, especially in its most severe form. In UC, the symptoms vary depending on the severity and c … (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Albireo to initiate A4250 ’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Shire ’s lanadelumab and SHP647 meet endpoints in respective trials
Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulce … (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Dinutuximab beta for the Treatment of Neuroblastoma
Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news

Aurinia begins voclosporin dosing in Phase III trial for LN
Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis (LN). (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news

Medical research funders and NGOs agree on new WHO clinical trial policies
The majority of medical research funders and international non-governmental organisations (NGOs) have agreed to implement the new World Health Organisation (WHO) standards for clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Genoa Pharmaceuticals, Dragonfly Therapeutics, Biomx
US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: Thermo Fisher Scientific, Norgine
US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news

Capecitabine improves post-surgery survival period in bile duct cancer patients
A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 17, 2017 Category: Pharmaceuticals Source Type: news

Interface Clinical Research develops new GP model to minimise clinical trial drop outs
Interface Clinical Services ’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - May 17, 2017 Category: Pharmaceuticals Source Type: news

Syndax ’s entinostat advances into second stage of Phase II trial for NSCLC
US-based biopharmaceutical firm Syndax Pharmaceuticals ’ entinostat has advanced into the second stage of Phase II of the ENCORE 601 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 17, 2017 Category: Pharmaceuticals Source Type: news

Immunovaccine to study DPX-Survivac in Phase II combination trial for DLBCL
Canadian-based immuno-oncology company Immunovaccine is set to evaluate its DPX-Survivac in combination with a PD-1 checkpoint inhibitor and a low-dose cyclophosphamide in its Phase II clinical trial to treat measurable or recurrent diffuse large B-C … (Source: Drug Development Technology)
Source: Drug Development Technology - May 16, 2017 Category: Pharmaceuticals Source Type: news

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 16, 2017 Category: Pharmaceuticals Source Type: news

Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer ’s disease
Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 16, 2017 Category: Pharmaceuticals Source Type: news

Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours
US-based biopharmaceutical company Syros Pharmaceuticals has started dosing patients in its Phase I clinical trial of SY-1365 for the treatment of patients with advanced solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - May 16, 2017 Category: Pharmaceuticals Source Type: news

Glenmark Pharmaceuticals to investigate GBR 1342 in Phase I trial for multiple myeloma
Indian pharmaceutical firm Glenmark Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase I clinical trial of GBR 1342 to treat patients with multi … (Source: Drug Development Technology)
Source: Drug Development Technology - May 15, 2017 Category: Pharmaceuticals Source Type: news

MMJ PhytoTech to initiate Phase II trial of PTL201 to treat MS symptoms
MMJ PhytoTech ’s Israeli division PhytoTech Therapeutics has obtained approvals from Ministry of Health and the Sheba Hospital regulatory body Helsinki, to initiate a Phase II clinical trial of its PTL201 for the treatment of spasticity related sympto… (Source: Drug Development Technology)
Source: Drug Development Technology - May 15, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca ’s Imfinzi meets primary endpoint in Phase III trial for stage III NSCLC
AstraZeneca and its biologics research and development arm MedImmune have reported positive results from the Phase III PACIFIC clinical trial of Imfinzi (durvalumab) to treat patients with locally advanced, unresectable (stage III) non-small-cell lun … (Source: Drug Development Technology)
Source: Drug Development Technology - May 15, 2017 Category: Pharmaceuticals Source Type: news

Gamlen Instruments Announces New Company Name
Gamlen Tableting has announced it is changing its trading name from 'Gamlen Tableting' to 'Gamlen Instruments' to acknowledge the company's established global presence as a leader in benchtop powder compaction instrumentation. (Source: Drug Development Technology)
Source: Drug Development Technology - May 15, 2017 Category: Pharmaceuticals Source Type: news

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Radicava ™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - May 14, 2017 Category: Pharmaceuticals Source Type: news

Mithra and Fuji Pharma to commence Estelle ’s PK trial in ASEAN markets
Belgium-based Mithra Pharmaceuticals and Japan's Fuji Pharma are set to begin a pharmacokinetic (PK) ethnobridging trial of Estelle in Japanese and Caucasian women. (Source: Drug Development Technology)
Source: Drug Development Technology - May 14, 2017 Category: Pharmaceuticals Source Type: news

Peloton starts dosing in Phase II trial of PT2385 to treat VHL-associated kidney cancer
US-based biotechnology firm Peloton Therapeutics has started dosing patients in its Phase II clinical trial of PT2385 for the treatment of kidney cancer caused by von Hippel-Lindau (VHL) disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 14, 2017 Category: Pharmaceuticals Source Type: news

Lilly ’s galcanezumab meets primary endpoint in three Phase III trials for migraine
US-based healthcare firm Eli Lilly and Company has reported positive results from three Phase III EVOLVE-1, EVOLVE-2 and REGAIN clinical trials of galcanezumab to prevent episodic and chronic migraine. (Source: Drug Development Technology)
Source: Drug Development Technology - May 14, 2017 Category: Pharmaceuticals Source Type: news

Application: Operating Reactor Systems for Process Research and Development
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software FlexySys. (Source: Drug Development Technology)
Source: Drug Development Technology - May 12, 2017 Category: Pharmaceuticals Source Type: news

What is the Compaction Triangle?
Gamlen presents three key parameters to visualising compacted material properties. (Source: Drug Development Technology)
Source: Drug Development Technology - May 12, 2017 Category: Pharmaceuticals Source Type: news

Sierra to amend two ongoing Phase I trials of SRA737 in UK
Canadian-based drug development firm Sierra Oncology has received clearance from UK regulatory authorities to amend two of its ongoing Phase I clinical trials of SRA737 within the country. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Corium ’s Corplex Donepezil demonstrates positive outcome in pilot BE trial
US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy subjects. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Aimmune ’s Phase III trial commences enrolment to study AR101 for peanut allergy
Aimmune Therapeutics has commenced patient enrolment in a Phase III RAMSES (ARC007) clinical trial of AR101 to treat peanut allergy. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: INC Research Holdings, WIRB-Copernicus Group (WCB)
US-based contract research organisation INC Research Holdings and contract commercial organisation inVentiv Health are set to merge to form the world ’s second biggest biopharmaceutical outsourcing provider. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: OptiNose, Dermira, Aadi Bioscience
OptiNose has completed a series D venture financing round to raise funds required for the commercialisation and launch of its lead product candidate, OPN-375, in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Top 10 Factors When Choosing a DLS Instrument
The physical components and features of a dynamic light scattering (DLS) instrument, along with the instrument's technical specifications, are important when purchasing a new system. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Boehringer begins enrolment in Phase II trial of BI 655064 to treat lupus nephritis
Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN). (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

DrugDev and Informa partner to enable easy site identification for clinical trials
DrugDev and Informa ’s Pharma Intelligence vertical, Citeline, have integrated their respective platforms to allow easy and efficient identification of ideal sites for conducting clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

OncoSec and Merck to begin Phase II combination trial to treat metastatic melanoma
US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic … (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news